If---if Pillar 2 is similar in indication to Pillar 1 or if the Endometriosis study currently underway comes out in the second half of 2014, there will be a confluence of:
1) Breast Reconstruction breaching the 20% market share ("Standard of Care" declaration requirement)
2) Ground breaking indication of Endometriosis identification for surgeons (currently no definitive method to identify cells)
3) Pillar 2 statistical indication of the superiority of the PINPOINT over anything existing in the operating room for surgeons, to plan, perform and prove blood profusion (the most important predictor of success for surgery)
4) 60-70 marketing personnel entering or already in the "productive" phase ("expected $1,000,000 in sales per year per person")
This time next year the Spy/Pinpoint/Luna machines will be flying off the shelf and hospitals all over the US will either have the machine or be talking about acquisition. I love it when a plan comes together.
Now I'm going to go way out on a limb and predict NVDQ will be above $35@ on Feb 19, 2015.